Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
Severe Erythema Multiforme - CORTICO
Phase 3
Not yet recruiting
- Conditions
- Erythema Multiforme
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 96
- Registration Number
- NCT06266221
Particulate Vs. Non-Particulate Steroid for Sacroiliac Joint Injection
Phase 4
Recruiting
- Conditions
- Sacroiliac Joint DysfunctionSacro-Iliac Spondylosis
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 230
- Registration Number
- NCT06268704
- Locations
- 🇺🇸
University of New Mexico Hospital, Albuquerque, New Mexico, United States
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Phase 1
Recruiting
- Conditions
- Multiple Myeloma in RelapseMultiple Myeloma, Refractory
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06225310
- Locations
- 🇺🇸
Berenson Cancer Center, West Hollywood, California, United States
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Early Phase 1
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06209606
- Locations
- 🇺🇸
Berenson Cancer Center, West Hollywood, California, United States
Comparison of Efficacy of Intra-articular Morphine vs Methylprednisolone in Patients With Knee Osteoarthritis.
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Henry Ford Health System
- Registration Number
- NCT06163755
TAP Block With Methyl-prednisolone as a Pain Treatment Modality After Total Abdominal Hysterectomy Procedures
Not Applicable
Completed
- Conditions
- UltrasoundLocal AnestheticPain, Acute
- Interventions
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Kasr El Aini Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06131593
- Locations
- 🇪🇬
Cairo university hospitals, kasralainy, Cairo, Egypt
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
Not yet recruiting
- Conditions
- Neuromyelitis OpticaEfgartigimod
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Feng Jinzhou
- Target Recruit Count
- 24
- Registration Number
- NCT06118398
Ketorolac Versus Corticosteroid Injections for Sacroiliac Joint Pain
Early Phase 1
Not yet recruiting
- Conditions
- Sacro-iliac Joint Pain
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 20
- Registration Number
- NCT06081101
- Locations
- 🇨🇦
Michael G. DeGroote Pain Clinic, Hamilton, Ontario, Canada
Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).
Phase 4
Recruiting
- Conditions
- Heart BlockBundle-Branch BlockAortic Stenosis
- Interventions
- Other: Placebo
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Hospital General Universitario de Alicante
- Target Recruit Count
- 100
- Registration Number
- NCT06076824
- Locations
- 🇪🇸
General University Hospital of Alicante, Alicante, Spain
Early and Late Prognosis in Patients With Guillain-Barre Syndrome
Phase 4
Recruiting
- Conditions
- Guillain-Barre Syndrome
- Interventions
- Drug: Intravenous Immunoglobulins, Human
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Target Recruit Count
- 450
- Registration Number
- NCT06041451
- Locations
- 🇨🇳
First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath